CLSA: Remains positive on the SBP GROUP industry; top picks INNOVENT BIO (01801) and SKB BIO (06990)

date
16:15 18/11/2026
avatar
GMT Eight
CLSA has assigned an "Outperform" rating to both INNOVENT BIO and SKB BIO, with target prices of HK$152 and HK$626.4, respectively.
CLSA issued a research report stating that the fundamentals of the SBP GROUP industry entering 2027 are better than market sentiment, with continued clinical validation, improved profit delivery, and strong out-licensing activity contrasting with weak liquidity and valuation. The bank expects major regulatory and clinical milestones to drive the next round of industry catalysts, while multinational pharmaceutical companies' demand for Chinese original innovation is expected to remain strong. The industry top picks are INNOVENT BIO (01801) and SKB BIO (06990), both rated "Outperform" with target prices of HK$152 and HK$626.4 respectively. The bank said that due to solid fundamentals, reasonable valuations, and catalysts in clinical, regulatory, and business development, it continues to hold a positive view on the SBP GROUP industry. It is bullish on INNOVENT BIO for its leading commercialization execution, diversified pipeline, and proven global innovation capabilities, and bullish on SKB BIO for the global proprietary rights potential of its sac-TMT and its multi-year profit growth prospects.